*,*::before,*::after{margin:0;padding:0;box-sizing:border-box} :root{ --bg:#0C1929; --bg2:#0F2038; --bg3:#152845; --bg4:#1A3254; --blue:#4DA6E0; --blue-light:#7BC1F0; --blue-dim:rgba(77,166,224,.12); --green:#22A066; --green-dim:rgba(34,160,102,.1); --red:#C03940; --red-dim:rgba(192,57,64,.09); --gold:#B8901E; --amber:#D08A2C; --white:#E8EEF5; --grey:#8BB0D0; --grey-dark:#1A3054; --font-serif:'Playfair Display',Georgia,serif; --font-sans:'Inter',system-ui,sans-serif; --font-mono:'IBM Plex Mono',ui-monospace,Menlo,monospace; } html{scroll-behavior:smooth} body{background:var(--bg);color:var(--white);font-family:var(--font-sans);font-size:16px;line-height:1.6;overflow-x:hidden} a{color:inherit} /* NAV (shared) */ nav{position:fixed;top:0;left:0;right:0;z-index:900;background:rgba(12,25,41,.94);backdrop-filter:blur(20px);-webkit-backdrop-filter:blur(20px);border-bottom:1px solid rgba(58,141,197,.14);height:62px;display:flex;align-items:center;justify-content:space-between;padding:0 5%} .nav-logo{font-family:var(--font-sans);font-weight:700;font-size:1.05rem;letter-spacing:.3px;color:var(--blue);text-decoration:none} .nav-logo span{color:rgba(232,238,245,.55);font-weight:400} .nav-links{display:flex;gap:1.7rem;list-style:none} .nav-links a{font-family:var(--font-sans);font-weight:500;font-size:.78rem;letter-spacing:.5px;color:var(--grey);text-decoration:none;transition:color .2s} .nav-links a:hover,.nav-links a.active{color:var(--white)} .nav-burger{display:none;flex-direction:column;gap:5px;background:none;border:none;cursor:pointer;padding:4px} .nav-burger span{display:block;width:22px;height:1.5px;background:var(--grey)} /* PAGE HEADER — clinical frame + restrained cypherpunk accent */ .pg-hero{padding:128px 5% 56px;position:relative;border-bottom:1px solid var(--grey-dark);overflow:hidden} .pg-hero::before{content:"";position:absolute;inset:0;background-image:repeating-linear-gradient(0deg,rgba(58,141,197,.035) 0,rgba(58,141,197,.035) 1px,transparent 1px,transparent 26px);pointer-events:none} .pg-hero-inner{max-width:1000px;margin:0 auto;position:relative;z-index:2} .channel-bar{display:flex;align-items:center;gap:14px;font-family:var(--font-mono);font-size:.7rem;letter-spacing:.5px;color:var(--grey);margin-bottom:18px;flex-wrap:wrap} .channel-bar .dot{width:7px;height:7px;border-radius:50%;background:var(--green);box-shadow:0 0 9px rgba(34,160,102,.7);flex-shrink:0} .channel-bar .ch{color:var(--blue-light)} .channel-bar .sep{color:rgba(122,144,168,.4)} .pg-tag{font-family:var(--font-sans);font-size:.7rem;font-weight:600;letter-spacing:3px;text-transform:uppercase;color:var(--blue);margin-bottom:10px} .pg-title{font-family:var(--font-serif);font-size:clamp(2.2rem,5vw,3.6rem);font-weight:700;line-height:1.12;color:var(--white)} .pg-title em{font-style:italic;color:var(--blue-light)} .pg-sub{font-size:.98rem;color:var(--grey);max-width:620px;margin:1.1rem 0 0;line-height:1.85} .sync-stamp{font-family:var(--font-mono);font-size:.72rem;color:rgba(122,144,168,.65);margin-top:20px;letter-spacing:.3px} .sync-stamp b{color:var(--blue-light);font-weight:500} /* DISCLOSURE BANNER — prominent, top of content */ .disclose-wrap{max-width:1000px;margin:36px auto 0;padding:0 5%} .disclose{display:grid;grid-template-columns:1fr 1fr;gap:14px} .disclose-card{background:var(--bg3);border:1px solid var(--grey-dark);padding:16px 20px} .disclose-card.med{border-left:2px solid var(--red)} .disclose-card.aff{border-left:2px solid var(--gold)} .disclose-card h4{font-family:var(--font-mono);font-size:.66rem;font-weight:600;letter-spacing:1.5px;text-transform:uppercase;margin-bottom:8px} .disclose-card.med h4{color:#C07070} .disclose-card.aff h4{color:#C8A44A} .disclose-card p{font-size:.78rem;color:rgba(232,238,245,.5);line-height:1.7;margin:0} /* SECTION */ .feed{max-width:1000px;margin:0 auto;padding:64px 5% 20px} .cat-hd{display:flex;align-items:baseline;gap:16px;margin:56px 0 26px;border-bottom:1px solid var(--grey-dark);padding-bottom:14px} .feed>.cat-hd:first-child{margin-top:0} .cat-icon{font-size:1.3rem;line-height:1} .cat-name{font-family:var(--font-serif);font-size:1.7rem;font-weight:700;color:var(--white)} .cat-count{font-family:var(--font-mono);font-size:.72rem;color:var(--grey);margin-left:auto;letter-spacing:.5px} /* DISPATCH DIVIDER */ .dispatch-divider{display:flex;align-items:center;gap:13px;margin:8px 0 32px;padding:14px 20px;background:var(--bg4);border:1px solid var(--grey-dark);border-left:2px solid var(--blue)} .dispatch-divider .dd-dot{width:8px;height:8px;border-radius:50%;background:var(--green);box-shadow:0 0 9px rgba(34,160,102,.7);flex-shrink:0} .dispatch-divider .dd-label{font-family:var(--font-mono);font-size:.78rem;font-weight:600;letter-spacing:1px;color:var(--blue-light)} .dispatch-divider .dd-meta{font-family:var(--font-mono);font-size:.7rem;color:var(--grey);margin-left:auto;letter-spacing:.3px} .dispatch-divider.archive{border-left-color:var(--grey);margin-top:64px} .dispatch-divider.archive .dd-dot{background:var(--grey);box-shadow:none} .dispatch-divider.archive .dd-label{color:var(--grey)} /* DISPATCH CARD */ .dsp{background:var(--bg3);border:1px solid var(--grey-dark);border-left:2px solid var(--blue);margin-bottom:14px;transition:border-color .2s} .dsp:hover{border-left-color:var(--blue-light)} .dsp-top{display:flex;align-items:center;gap:12px;padding:12px 20px;border-bottom:1px solid rgba(26,48,84,.7);flex-wrap:wrap;font-family:var(--font-mono);font-size:.68rem} .dsp-ref{color:var(--blue-light);letter-spacing:.5px;font-weight:500} .dsp-date{color:rgba(122,144,168,.7);letter-spacing:.3px} .dsp-grade{margin-left:auto;font-weight:600;letter-spacing:1px;text-transform:uppercase;padding:2px 9px;border:1px solid;font-size:.62rem;white-space:nowrap} .g-meta{color:var(--green);background:var(--green-dim);border-color:rgba(34,160,102,.3)} .g-cohort{color:var(--blue-light);background:var(--blue-dim);border-color:rgba(58,141,197,.3)} .g-exp{color:#C8A44A;background:rgba(200,164,74,.08);border-color:rgba(200,164,74,.28)} .g-review{color:var(--grey);background:rgba(122,144,168,.07);border-color:rgba(122,144,168,.25)} .dsp-body{padding:18px 20px} .dsp-headline{font-family:var(--font-sans);font-size:1rem;font-weight:600;color:var(--white);line-height:1.5;margin-bottom:9px} .dsp-text{font-size:.9rem;color:rgba(232,238,245,.62);line-height:1.82} .dsp-text b{color:var(--blue-light);font-weight:600} .dsp-data{display:flex;gap:10px;flex-wrap:wrap;margin:12px 0 4px} .dsp-pill{font-family:var(--font-mono);font-size:.72rem;color:rgba(232,238,245,.7);background:rgba(58,141,197,.07);border:1px solid rgba(58,141,197,.16);padding:4px 10px} .dsp-pill b{color:var(--blue-light);font-weight:600} .dsp-foot{display:flex;align-items:center;gap:14px;padding:11px 20px;border-top:1px solid rgba(26,48,84,.7);flex-wrap:wrap} .dsp-src{font-family:var(--font-mono);font-size:.72rem;color:var(--grey);letter-spacing:.2px} .dsp-link{font-family:var(--font-mono);font-size:.72rem;color:var(--blue);text-decoration:none;margin-left:auto;border:1px solid rgba(58,141,197,.3);padding:4px 12px;transition:all .18s;white-space:nowrap} .dsp-link:hover{background:var(--blue-dim);color:var(--blue-light)} .dsp-flag{font-family:var(--font-mono);font-size:.66rem;font-weight:600;letter-spacing:.5px;text-transform:uppercase;padding:3px 9px;border:1px solid} .flag-offlabel{color:#C8A44A;background:rgba(200,164,74,.07);border-color:rgba(200,164,74,.22)} .flag-rx{color:var(--blue);background:var(--blue-dim);border-color:rgba(58,141,197,.25)} /* INVESTIGATIONAL — quarantine treatment */ .dsp.invest{border-left-color:var(--amber);background:linear-gradient(180deg,rgba(208,138,44,.05),transparent 60%),var(--bg3)} .dsp.invest .dsp-top{border-bottom-color:rgba(208,138,44,.2)} .dsp.invest .dsp-foot{border-top-color:rgba(208,138,44,.2)} .invest-ribbon{display:flex;align-items:center;gap:8px;font-family:var(--font-mono);font-size:.68rem;font-weight:600;letter-spacing:1.2px;text-transform:uppercase;color:var(--amber);background:rgba(208,138,44,.09);border:1px solid rgba(208,138,44,.28);padding:7px 14px;margin-bottom:0} .invest-ribbon::before{content:"";width:7px;height:7px;background:var(--amber);box-shadow:0 0 8px rgba(208,138,44,.6)} .g-invest{color:var(--amber);background:rgba(208,138,44,.08);border-color:rgba(208,138,44,.32)} /* LIMITATIONS BLOCK */ .limits{background:var(--bg3);border:1px solid var(--grey-dark);border-left:2px solid var(--grey);padding:22px 24px;margin-bottom:14px} .limits h4{font-family:var(--font-mono);font-size:.7rem;font-weight:600;letter-spacing:1.5px;text-transform:uppercase;color:var(--grey);margin-bottom:14px} .limits ul{list-style:none;display:flex;flex-direction:column;gap:11px} .limits li{font-size:.87rem;color:rgba(232,238,245,.6);line-height:1.7;padding-left:18px;position:relative} .limits li::before{content:"//";position:absolute;left:0;color:rgba(122,144,168,.5);font-family:var(--font-mono);font-size:.78rem} .limits li b{color:var(--white);font-weight:600} /* BOTTOM LINE */ .bottomline{max-width:1000px;margin:48px auto 0;padding:0 5%} .bl-inner{background:var(--bg4);border:1px solid var(--grey-dark);padding:32px 30px;text-align:center} .bl-tag{font-family:var(--font-mono);font-size:.68rem;letter-spacing:2px;text-transform:uppercase;color:var(--blue);margin-bottom:12px} .bl-inner p{font-size:1.02rem;color:rgba(232,238,245,.78);line-height:1.85;max-width:680px;margin:0 auto} .bl-inner p b{color:var(--white)} /* CTA STRIP */ .cta-strip{max-width:1000px;margin:40px auto 0;padding:0 5%} .cta-inner{display:flex;gap:12px;justify-content:center;flex-wrap:wrap} .cta-btn{font-family:var(--font-sans);font-weight:600;font-size:.75rem;letter-spacing:1.5px;text-transform:uppercase;padding:12px 26px;text-decoration:none;border:1px solid;transition:all .2s} .cta-btn.blue{color:var(--white);background:var(--blue);border-color:var(--blue)} .cta-btn.blue:hover{background:var(--blue-light);border-color:var(--blue-light)} .cta-btn.ghost{color:var(--grey);border-color:rgba(122,144,168,.3)} .cta-btn.ghost:hover{color:var(--white);border-color:rgba(122,144,168,.5)} /* FOOTER (shared) */ footer{background:var(--bg);border-top:1px solid var(--grey-dark);padding:40px 5%;text-align:center;margin-top:64px} .ft-logo{font-family:var(--font-sans);font-weight:700;font-size:1.1rem;letter-spacing:.3px;color:var(--blue);margin-bottom:4px} .ft-logo span{color:rgba(232,238,245,.4);font-weight:400} .ft-tag{font-family:var(--font-sans);font-size:.75rem;letter-spacing:2px;text-transform:uppercase;color:var(--grey);margin-bottom:1.4rem;opacity:.6} .ft-links{display:flex;justify-content:center;gap:2rem;list-style:none;flex-wrap:wrap;margin-bottom:1.4rem} .ft-links a{font-family:var(--font-sans);font-size:.75rem;font-weight:500;color:var(--grey);text-decoration:none;transition:color .2s} .ft-links a:hover{color:var(--white)} .ft-copy{font-size:.72rem;color:rgba(232,238,245,.15)} /* ANIM */ .fi{opacity:0;transform:translateY(16px);transition:opacity .5s ease,transform .5s ease} .fi.vis{opacity:1;transform:translateY(0)} @media(max-width:760px){ .nav-links{display:none;flex-direction:column;position:absolute;top:62px;left:0;right:0;background:rgba(12,25,41,.98);padding:20px 5%;gap:14px;border-bottom:1px solid var(--grey-dark)} .nav-links.open{display:flex} .nav-burger{display:flex} .pg-hero{padding:104px 5% 40px} .disclose{grid-template-columns:1fr} .feed{padding:44px 5% 10px} .cat-hd{margin:40px 0 20px} .cat-name{font-size:1.4rem} .dsp-grade{margin-left:0} .dsp-link{margin-left:0} }
RESEARCH CHANNEL // ACTIVE · DISPATCH-2026-06-20 · REF 7bbbff97
Evidence Digest

Research Dispatch

A running log of the latest peer-reviewed research on DHT, hair loss, and testosterone. Every entry carries an evidence grade and a link to the source. Findings are reported as published — they are not recommendations.

LAST SYNC: 2026-06-20 · SOURCES VERIFIED: 14 · FILTER: peer-reviewed / clinical-trial registries only

⚕ Medical Disclaimer

Educational content only. Nothing here is medical advice, a diagnosis, or a treatment recommendation. Drug efficacy figures are reported from individual studies and do not predict your result. Several options below are off-label or prescription-only. Consult a qualified physician before starting, stopping, or changing any medication, supplement, or protocol.

⚐ Affiliate Disclosure (FTC)

HairMaxxProtocol.com may earn a commission from some links to products or telemedicine services. This never changes the evidence we report, what we grade, or what we recommend. We disclose limited and conflicting evidence honestly — including where the data argues against a product category.

DISPATCH · 2026-06-20 REF 7bbbff97 · 5 sources verified
🧬 Hair & DHT UPDATE
RX-07 · #1d6e 2025 Meta-Analysis · 7 RCTs
Minoxidil + finasteride together beats minoxidil alone — and the combo's finasteride stays under the side-effect threshold.
A meta-analysis of 7 RCTs (N=396) found topical minoxidil + finasteride significantly outperformed minoxidil alone, with no treatment-emergent sexual side effects. Plasma finasteride stayed below 1 ng/mL — under the level linked to sexual dysfunction.
Density +9.22 hairs/cm² Diameter +2.26 µm (p=0.005) Plasma fin <1 ng/mL
Topical fin: off-label / compounded Front Med ↗
RX-08 · #9a44 2024 Systematic Review · 9 studies
Head-to-head: dutasteride drove 90–110% greater hair-count gains than finasteride.
A systematic review found dutasteride 0.5–2.5 mg produced 90–110% greater hair-count increases than finasteride 1 mg, via dual Type 1+2 inhibition (~90% DHT suppression vs ~70%). Adverse-event rates were comparable — but dutasteride's ~5-week half-life (vs finasteride's 6–8 hours) means any side effects could linger longer.
Dutasteride DHT ↓~90% Finasteride ↓~70% Hair count +90–110%
Dutasteride off-label (US) Prescription only Dermatol Rep ↗
RX-09 · #4c20 2020 Systematic Review · N=381
Natural blockers, quantified: saw palmetto helps modestly — but the evidence is low-quality.
A review of 9 studies found saw palmetto improved overall hair quality in 60% of users and raised total count by 27% — but it was inferior to finasteride in the only head-to-head, and the authors stress robust data are lacking. A separate RCT of 76 men found pumpkin seed oil (400 mg/day) beat placebo at 24 weeks. A reasonable mild, low-risk option — not a finasteride replacement.
Hair count +27% Quality ↑ in 60% Evidence: low
Graded honestly on the supplement page. Skin Appendage Disord ↗
Investigational · not yet available to patients
RX-10 · #7e9f Phase 1/2 · preclinical Early-Stage
A non-hormonal pipeline is forming: a stem-cell-reactivating injectable, exosomes, and a CXCL12 antibody.
AMP-303 (Pelage/Amplifica) is a non-hormonal injectable that reactivates follicle stem cells; first-in-human data showed increased non-vellus hair counts, with durability and repeat-dosing still being studied. Exosome therapies (cell-derived growth-signal vesicles) show biologic promise but lack standardization. A CXCL12-neutralizing antibody promoted growth in AGA models (preclinical). None are FDA-approved or available.
Status: first-in-human / preclinical · do not seek to obtain
💪 Testosterone UPDATE
TX-08 · #b3c7 2013 Meta-Analysis
Losing excess fat is the single biggest natural lever on testosterone — and it's dose-dependent.
A meta-analysis found the degree of weight loss was the best predictor of testosterone rise, via either low-calorie diet or bariatric surgery. The flip side: a chronic caloric deficit suppresses testosterone — under starvation the body deprioritizes reproduction. If you're cutting, do it in phases, not indefinitely.
5% loss → +~58 ng/dL ~10% → +~84 ng/dL Bariatric → +~251 ng/dL
The highest-yield intervention on this page. Eur J Endocrinol ↗
TX-09 · #e051 2018 RCT · Micronutrient
Your vitamin D may underperform without magnesium — and zinc has a hard ceiling.
The enzymes that activate vitamin D are magnesium-dependent, so correcting low magnesium improves vitamin D status and metabolism (RCT evidence). Practically: D3 alone can fall flat in men low on magnesium. Zinc is the mirror image — necessary for testosterone, but >40 mg/day long-term drives copper deficiency, which harms testosterone and immunity. Test, then correct; don't megadose.
Vit D activation = Mg-dependent Zinc ceiling ~40 mg/day Zinc RDA 11 mg
Affects the Vitamin D & Zinc stack entries. Am J Clin Nutr ↗
TX-10 · #2fa8 2020 Evidence Audit
Two popular "boosters" don't deliver: maca doesn't raise testosterone, and D-aspartic acid may lower it.
From the supplement-composition literature: maca enhances libido but does not change testosterone; D-aspartic acid showed an early rise at 2.66 g/day that later studies failed to replicate — one 2017 trial found a decrease at 6 g/day. Ashwagandha, fenugreek, and DHEA show modest effects, mostly only when you're deficient. Test before you stack.
Why our supplement grading stays skeptical. World J Men's Health ↗

What actually moves testosterone — ranked by effect size

DISPATCH · 2026-06-19 ARCHIVE · first digest
🧬 Hair & DHT 06 ENTRIES
RX-01 · #a17e 2025 Network Meta-Analysis · 33 studies
Dutasteride ranked most effective overall — but the FDA-approved standard remains oral finasteride + topical minoxidil.
Across 33 pooled studies, oral dutasteride 0.5 mg/day ranked as the single most effective treatment. Among FDA-approved options, topical minoxidil 5% and oral finasteride 1 mg/day remain first-line. Topical finasteride 0.25% reduced scalp DHT comparably to oral, with potentially lower systemic exposure.
Topical fin DHT ↓ 68–75% Oral fin DHT ↓ 62–72%
Dutasteride off-label for hair (US) Prescription only J Cosmet Dermatol ↗
RX-02 · #c4b9 2025 Comparative Review
Oral minoxidil (2.5–5 mg) matches topical 5% for hair density — at the cost of more body-hair growth.
Low-dose oral minoxidil produced terminal-hair-density gains on par with topical 5%. The trade-off is systemic: unwanted hair growth (hypertrichosis) was far more common.
Hypertrichosis oral ~49% Topical ~25%
Oral minoxidil off-label Prescription only J Cosmet Dermatol ↗
RX-03 · #7f02 2025 5-Year Cohort
Five-year real-world data: finasteride helped ~86% of men; dutasteride ~90%.
In a Korean cohort followed for five years, finasteride improved hair in 85.7% of patients and dutasteride in 89.9%. A newer lower-dose 0.2 mg dutasteride formulation (2024) showed non-inferior efficacy with fewer reported sexual side effects than the 0.5 mg dose.
Prescription only Ann Dermatol ↗
RX-04 · #e3a0 2025 Comparative Trials
"Natural" DHT blockers underperform the drugs — by roughly half.
Across comparative trials, plant-derived 5α-reductase inhibitors (saw palmetto, pumpkin seed oil) showed roughly ~30% of the effect seen with finasteride's ~70% at best. They are a milder, lower-risk option — not an equivalent substitute. We grade them honestly on the supplement page.
Setting expectations, not selling miracles. See sources ↗
Investigational · not yet available to patients
RX-05 · #b8c1 Phase II/III Trial-Stage
Long-acting injectable 5α-reductase inhibitors aiming for monthly — or twice-yearly — dosing.
PLGA-microsphere depot technology is in Phase II/III trials (NCT04945226, NCT06916793) to replace daily pills with infrequent injections. A dermal sheath cell (DSC) therapy was approved in Japan in 2024, with stronger results reported in older women than in men. None of these are FDA-approved or commercially available in the US.
Status: clinical trials only · do not seek to obtain Ann Dermatol ↗
RX-06 · #2dd4 2025 Different Mechanism
Note: alopecia areata is a different disease — autoimmune, not DHT-driven.
Alopecia areata is increasingly understood as an autoimmune attack on the follicle, distinct from the DHT-driven miniaturization this site addresses. It requires a different approach. Early bone-marrow MSC stem-cell trials report 50–52% improvement, but samples are small and long-term safety is unestablished. Included for context — this protocol does not target alopecia areata.
Status: small trials · context only Cell Transplant ↗
💪 Testosterone 07 ENTRIES
TX-01 · #f019 2026 Population Data · NHANES
Young men's testosterone has fallen ~25% in a generation — independent of aging or weight.
NHANES data (1999–2016) show total testosterone in men aged 15–39 dropping from 605 to 451 ng/dL. The decline runs ~0.56%/year and persists after controlling for aging, obesity, and assay differences — pointing to lifestyle and environmental drivers.
1999: 605 ng/dL 2016: 451 ng/dL −0.56%/yr
This is why the protocol exists. Int J Mol Sci ↗
TX-02 · #5ab7 2026 Longitudinal Cohort
A second independent cohort confirms the slide: −33% over 20 years.
An Air Force veterans cohort (1982–2002) saw mean total testosterone fall from 638 to 431 ng/dL. Danish and Finnish cohorts born later in the 20th century also measured significantly lower than their predecessors — the decline replicates across countries.
Generational, cross-national, replicated. Int J Mol Sci ↗
TX-03 · #91c2 2026 Controlled Experiment
One week of 5-hour nights cut daytime testosterone by 10–15%.
In young healthy men, a single week of sleep restriction lowered daytime testosterone by 10–15%; 24 hours of total deprivation dropped it 25–30%. Fragmentation matters as much as duration — broken sleep blunts the overnight testosterone surge. The single most controllable lever on this list.
5h × 1 week: −10–15% 24h awake: −25–30%
Reinforces Protocol Rule on sleep. Int J Mol Sci ↗
TX-04 · #03de 2025 Cross-Sectional · n=50
In men 18–22, what moved testosterone: training up, junk food down.
A study of 50 young men found hypertrophy training (β=20.3), >60 min/day sunlight (β=10.3), and a non-vegetarian diet (β=8.7) associated with higher testosterone. Negatives: under-6h sleep (β=−18.2), tobacco (β=−15.6), junk food (β=−14.5), carbonated drinks (β=−10.2). BMI was not significant in this young cohort. Small, observational — directional, not definitive.
Associations from a small sample. Reprod Biol Endocrinol ↗
TX-05 · #6e44 2026 Review · Environmental
Everyday endocrine disruptors are associated with lower testosterone.
Phthalates, BPA, PFAS, microplastics, air pollution (PM2.5), and pesticides (atrazine, glyphosate) are associated with reduced testosterone — reviews cite up to ~35% reduction potential, with some pesticides shown to directly inhibit Leydig-cell synthesis. These are correlational and exposure-dependent, not a verdict on any individual. Reducing plastic food contact and processed exposure is low-risk and sensible.
Associated with — not proven to cause your levels. Int J Mol Sci ↗
TX-06 · #a8f3 2026 Review · Pharmacology
Some common medications suppress testosterone — but never stop them on your own.
Reviews report opioids suppressing testosterone by nearly 50% via GnRH inhibition; statins lowering total T modestly (~0.66 nmol/L); and SSRIs and glucocorticoids interfering with the hormonal axis. This is information for a conversation with your doctor — not a reason to discontinue prescribed medication. Obesity remains a major driver (BMI >35–40 linked to up to 50% lower T), though stable-weight men still declined ~19% over 20 years.
Discuss with a physician before any change. Int J Mol Sci ↗
TX-07 · #d520 2020 Supplement Audit
Most "testosterone-boosting" supplements have no data behind them — and some lower it.
A PubMed audit of T-booster supplements found only 24.8% had any data supporting an increase, 61.5% had no published data at all, and 18.3% were associated with a decrease. The FDA has issued warnings for products containing hidden steroids. Vitamin D (when deficient) and ashwagandha have the most credible signals; we grade each on evidence quality, not hype.
Support increase: 24.8% No data: 61.5% Decrease: 18.3%
Why our supplement table stays skeptical. World J Men's Health ↗
Conflicting Evidence & Limits FULL DISCLOSURE

Where the evidence is mixed — stated plainly

📡 Clinical Trials Watch MONITORING
Tracking only · nothing below is available to patients
Injectable 5α-reductase inhibitors — depot/mesotherapy vs oral · NCT04945226, NCT06916793
Alopecia areata stem cells — bone-marrow MSC protocols (autoimmune target, distinct from DHT)
Probiotic × testosterone RCTs — early-stage, aging populations
We update this page when registry status changes.
// Signal, not noise

No miracle cures surfaced this cycle. The strongest, most actionable signals stay boring and proven: fix sleep, train for hypertrophy, cut ultra-processed food and plastic exposure for testosterone — and for hair loss, the evidence still points to finasteride or dutasteride combined with minoxidil, under a doctor's care.

See the Protocol → Full Source List →